Please wait while the formulary information is being retrieved.
FLOLAN (EPOPROSTENOL SODIUM (GLYCINE))
- Pulmonary arterial hypertension
- Flolan Intravenous Solution
- Epoprostenol Iv Solution
- Epoprostenol (glycine) Intravenous Solution
- By Indication
0.5 mg intravenous solution
- Dosage information is not available
1.5 mg intravenous solution
- Dosage information is not available
(glycine) 0.5 mg intravenous solution
- Dosage information is not available
(glycine) 1.5 mg intravenous solution
- Dosage information is not available
epoprostenol (glycine) 0.5 mg intravenous solution
- Dosage information is not available
epoprostenol (glycine) 1.5 mg intravenous solution
- Dosage information is not available
Pulmonary arterial hypertension
- Infuse 20 nanogram/kg/minute via infusion pump by continuous infusionroute
- Infuse 40 nanogram/kg/minute via infusion pump by continuous infusionroute
- Infuse 25 nanogram/kg/minute via infusion pump by continuous infusionroute
- Infuse 16 nanogram/kg/minute via infusion pump by continuous infusionroute
- None
Contraindicated
- None
Severe
Moderate
- None
- Severe chronic heart failure
Contraindicated
- Pulmonary edema
Severe
Moderate
- Increased risk of bleeding
FLOLAN (EPOPROSTENOL SODIUM (GLYCINE))
- Pulmonary arterial hypertension
- Administration site infection
- Bacterial sepsis
- Hemorrhage
- Hypotension
- Skin ulcer
- Tachycardia
- Agitation
- Chest pain
- Diarrhea
- Dizziness
- Eczema
- Flu-like symptoms
- Flushing
- Headache disorder
- Jaw pain
- Musculoskeletal pain
- Myalgias
- Nausea
- Nervousness
- Skin rash
- Symptoms of anxiety
- Urticaria
- Vomiting
More Frequent
Severe
Less Severe
- Thrombocytopenic disorder
- Acute abdominal pain
- Anorexia
- Bradycardia
- Hypesthesia
- Paresthesia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anemia
- Hepatic failure
- High output heart failure
- Pancytopenia
- Pulmonary thromboembolism
- Splenomegaly
- Worsening of chronic heart failure
Less Severe
- Hyperthyroidism
- Pulmonary edema
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Epoprostenol
Safety and efficacy not established age < 18 years.
- 1 Day – 18 Years
- Safety and efficacy not established age < 18 years.
Epoprostenol
- Severity Level:
2
- Additional Notes:
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Epoprostenol
None
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Pulmonary arterial hypertension | |
| I27.0 | Primary pulmonary hypertension |
| I27.21 | Secondary pulmonary arterial hypertension |
| 0-9 | A-Z |
|---|---|
| I27.0 | Primary pulmonary hypertension |
| I27.21 | Secondary pulmonary arterial hypertension |
Formulary Reference Tool